Highlights

  • CSL (ASX:CSL) reported a statutory net loss of US$2.6 billion in FY26, largely due to US$7.1 billion of non-cash impairments.
  • Underlying NPATA was US$3.1 billion, while Operating Cash Flow remained strong at US$3.5 billion.
  • CSL Behring showed improving momentum, with immunoglobulin performance strengthening in the second half.
  • FY27 guidance points to underlying NPAT growth of around 5%, with cost savings and restructuring progress key focus areas.

CSL (ASX:CSL) delivered one of the most challenging headline results in its recent history, reporting a significant statutory loss due to large Impairment charges. However, investors focused on the underlying Business performance, improving plasma trends, cost reductions and FY27 guidance that suggested a return toward growth. The key question now is whether CSL can convert operational improvements into sustained Earnings recovery after several years of weaker performance.

A reset year that changed market expectations

CSL's FY26 result for the year ended 30 June 2026 presented a sharp contrast between reported earnings and underlying operations.

The company recorded a statutory net loss of US$2.6 billion, primarily due to US$7.1 billion of impairments.

Despite the headline loss, investor sentiment improved as the market focused on the company's outlook rather than the accounting impact of the write-downs.

Management described FY26 as a year of reset, with a focus on returning the business to sustainable growth.

The market reaction reflected expectations that the impairment cycle was largely complete and that operational improvements could become more visible in future periods.

Stripping out the noise: what CSL actually earned

The majority of the FY26 loss was non-cash in nature.

Underlying NPATA was US$3.1 billion, down 2%, while underlying NPAT declined 3% to US$2.8 billion.

Operating cash flow remained steady at US$3.5 billion.

Group Revenue declined 1% on a constant-currency basis to US$15.8 billion.

The US$7.1 billion impairment charge included approximately US$5.5 billion recorded in the second half.

Major components included:

  • around US$1.7 billion impairment of Vifor goodwill;
  • approximately US$1.5 billion against the Ferinject iron intangible;
  • US$738 million against Venofer;
  • US$931 million related to the Lengnau Manufacturing facility;
  • US$590 million associated with the discontinued Arcturus sa-mRNA collaboration.

Management expects FY27 impairments to reduce significantly to around US$200 million, suggesting that much of the restructuring and portfolio reset has already been recognised.

The divisions: plasma stabilises while Vifor remains under pressure

CSL Behring remains the core earnings driver.

The plasma business generated US$11.4 billion in revenue, down 1%.

However, the more important trend was improvement during the second half.

Immunoglobulin revenue was broadly stable for the full year but strengthened in the second half, supported by continued Demand for CSL's key plasma-derived products.

Haemophilia revenue declined 1%, although gene therapy product Hemgenix increased 25%.

Albumin revenue declined 17% due to cost pressures in China.

CSL Seqirus, the influenza Vaccine business, declined 8% to US$2.0 billion.

Seasonal influenza revenue increased 4% to US$1.6 billion, and CSL confirmed the operational separation of Seqirus had been completed.

CSL Vifor revenue increased 3% to US$2.4 billion, supported by 18% growth in nephrology.

However, Vifor remains the most challenged division, with iron-product revenue falling 16%.

Management expects Vifor revenue to decline around 25% in FY27 as reimbursement changes affect demand and competition increases.

What is driving the stock

The market reaction was driven less by FY26 performance and more by the outlook.

CSL guided to underlying NPAT growth of approximately 5% in FY27, ahead of previous market expectations.

The company expects CSL Behring to deliver mid-single-digit growth, Seqirus to contribute low-single-digit growth, while Vifor remains a drag.

Cost reduction is another important factor.

CSL delivered US$176 million of cost savings in FY26 as part of a broader program targeting US$400 million in FY27 and up to US$550 million by FY28.

The program includes workforce reductions and operational simplification.

CSL also completed a A$1 billion share buyback in FY26 and authorised a further A$1.1 billion program.

The full-year Dividend was maintained at US$2.92 per share, including a US$1.62 final dividend.

For investors, the recovery case is based on improving operating performance rather than the FY26 headline result.

The growth story management is asking investors to support

The Long-term Growth opportunity remains centred on CSL Behring and the plasma business.

CSL is the world's largest plasma collector, giving it scale advantages across collection, manufacturing and distribution.

The company is investing in collection technology and efficiency initiatives designed to reduce plasma costs while supporting long-term demand growth for immunoglobulin products.

Additional growth opportunities include Hemgenix, the gene-therapy pipeline, continued immunoglobulin demand across neurological conditions and a simplified post-Seqirus structure.

The separation of Seqirus could also provide greater strategic clarity by creating a more focused plasma and biotherapies business.

If cost reductions translate into higher margins and plasma demand continues improving, CSL could begin rebuilding the earnings profile that previously supported a premium valuation.

The risks that remain

Despite the improved outlook, several risks remain.

CSL has missed previous long-term growth expectations, meaning execution remains a key issue.

Vifor remains a significant challenge, with a projected revenue decline in FY27 creating pressure on group growth.

The plasma business also faces risks from collection costs, competitive pressure and potential changes in treatment approaches.

Seqirus remains exposed to seasonal influenza demand, vaccine policy and broader healthcare conditions.

Leadership transition is another consideration, with the company operating under an interim CEO.

Currency movements can also materially affect reported results because CSL generates earnings globally while reporting in US dollars.

After the share-price recovery, expectations have increased again, meaning operational delivery will be closely scrutinised.

What Investors Should Watch Next

The appointment of a permanent CEO will be an important governance milestone.

Operationally, investors should focus on the H1 FY27 result in February 2027.

Key indicators include:

  • whether immunoglobulin momentum continues;
  • delivery of planned cost savings;
  • progress on Margin recovery;
  • Vifor performance against guidance;
  • timing of the Seqirus separation;
  • any additional impairment charges.

These factors will determine whether the current recovery in sentiment develops into a sustained earnings improvement.

The Bottom Line

CSL (ASX:CSL) delivered a difficult FY26 result on paper, but the underlying business showed signs of stabilisation.

The large statutory loss reflected significant impairments rather than a collapse in operating cash generation, while plasma performance improved and cost reductions gained momentum.

The recovery case now depends on execution.

CSL must demonstrate that the plasma business can return to growth, cost savings can improve margins and weaker divisions can be managed effectively.

The market has shifted from questioning whether CSL can stabilise to assessing whether it can deliver renewed growth.